The safety of biologic agents in early rheumatoid arthritis

Clinical and Experimental Rheumatology

Volumn 21, Issue 5 SUPPL. 31, 2003, Pages

  Kavanaugh, Arthur ^a   Keystone, Edward C ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

Biologic agents; Pharmacovigilance; Rheumatoid arthritis; Safety; TNF inhibitors

Indexed keywords

ADALIMUMAB; BIOLOGICAL PRODUCT; ETANERCEPT; INFLIXIMAB; LENERCEPT; TUMOR NECROSIS FACTOR ALPHA RECEPTOR BLOCKING AGENT; UNCLASSIFIED DRUG;

ARTICLE; BINDING AFFINITY; BLOOD DYSCRASIA; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DATA ANALYSIS; DEMYELINATING DISEASE; DRUG BINDING; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG HALF LIFE; DRUG SURVEILLANCE PROGRAM; HODGKIN DISEASE; HUMAN; INFORMATION PROCESSING; LIVER DYSFUNCTION; LYMPHOMA; MULTIPLE SCLEROSIS; NONHODGKIN LYMPHOMA; OPTIC NERVE DISEASE; PATIENT MONITORING; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; RISK BENEFIT ANALYSIS; SIDE EFFECT; SKIN CANCER; SOLID TUMOR; TUBERCULOSIS; UPPER RESPIRATORY TRACT INFECTION;

ANTIBODIES, MONOCLONAL; ARTHRITIS, RHEUMATOID; BIOLOGICAL PRODUCTS; CLINICAL TRIALS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOGLOBULIN G; MALE; RECEPTORS, TUMOR NECROSIS FACTOR; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 0142124925     PISSN: 0392856X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. BATHON J, MARTIN R, FLEISCHMANN R, et al.: A comparison of etanercept and methotrexate in patient with early rheumatoid arthritis. N Engl J Med 2000; 343: 1586-93.
2. DORAN M, GABRIEL S: Infections in rheumatoid arthritis - A new phenomenon? J Rheumatol 2001; 28: 1942-3.
3. HERNANDEZ-CRUZ B, SIFUENTES-OSORNIO J, ROSALES P, DIAZ-JOUANEN E: Mycobacterium tuberculosis infection in patients with systemic rheumatic diseases. A case series. Clin Exp Rheumatol 1999; 17: 289-96.
4. MATTESON E, HICKEY AM MAGUIRE A, et al.: Occurrence of neoplasia in patients with rheumatoid arthritis enrolled in a DMARD registry. J Rheumatol 1991; 18: 809-14.
5. GRIDLEY G, McLAUGHLIN J, EKBOM A, et al.: Incidence of cancer among patients with rheumatoid arthritis. J Natl Cancer Institute 1993; 85: 307-11.
6. VAN DEN BORNE B, LANDEWE R, HOUKES I, et al.: No increased risk of malignancies and mortality in cyclosporin A-treated patients with rheumatoid arthritis. Arthritis Rheum 1998; 41: 1930-7.
7. ROBINSON D, WOERNER M, POLLACK S, LERNER G: SUBJECT selection biases in clinical trials: data from a multicenter schizophrenia treatment study. J Clin Psychopharmacol 1996; 16: 170-6.
8. TEJEDA H, GREEN S, TRIMBLE E, et al.: Representation of African-Americans, Hispanics and whites in National Cancer Institute cancer treatment trials. J Natl Can Instit 1996; 88: 812-6.
9. ROUTLEDGE P: 150 years of pharmacovigilance. Lancet 1998; 351: 1200-1.
10. KESSLER D: Introducing MedWatch: A new approach to reporting medication and device adverse effects and product problems. JAMA 1993; 269: 2765-8.
11. MEYBOOM R, EGBERTS A, GRIBNAU F, HEKSTER Y: Pharmacovigilance in perspective. Drug Safety 1999; 21: 429-47.
12. ELAND IA, BELTON KJ, VAN GROOTHEEST AC, MEINERS AP, RAWLINS MD, STRICKER BH: Attitudinal survey of voluntary reporting of adverse drug reactions. Br J Clin Pharmacol 1999; 48: 623-7.
13. SCOTT H, ROSENBAUM S, WATERS W, et al.: Rhode Island physicians' recognition and reporting of adverse drug reactions. R I Med J 1987; 70: 311-6.
14. RAWLINS MD: Pharmacovigilance: paradise lost, regained, or postponed? J R Coll Physicians Lond 1995; 29: 41-9.
15. MARTIN RM, KAPOOR KV, WILTON LV, MANN RD: Underreporting of suspected adverse drug reactions to newly marketed ("black triangle") drugs in general practice: observational study. BMJ 1998; 317: 119-20.
16. HEELEY E, RILEY J, LAYTON D, WILTON L, SHAKIR S: Prescription-event monitoring and reporting of adverse drug reactions. Lancet 2001; 358: 1872-3.
17. WEBER J: Epidemiology of adverse reactions to nonsteroidal antiinflammatory drugs. Adv Inflam Res 1984; 6: 1-7.
18. MacDONALS T, MORANT S, ROBINSON G, et al.: Association of upper gastrointestinal toxicity of non-steroidal anti-inflammatory drugs with continued exposure: A cohort study. BMJ 1997; 315: 1333-7
19. SCHAIBLE T: Long term safety of infliximab. Can J Gastroenterol 2000; 14 (Suppl. C): 29C-32C.
20. MORELAND L, COHEN S, BAUMGARTNER S, et al.: Longterm safety and efficacy of etanercept in patients with rheumatoid arthritis. J Rheumatol 2001; 28: 1238-44.
21. KEANE J, GERSHON S, WISE R, et al.: Tuberculosis associated with infliximab, a tumor necrosis factor α-neutralizing agent. N Engl J Med 2001; 345: 1098-104.
22. MOHAN V, SCANGA C, YU K, et al.: Effects of tumor necrosis factor alpha on host immune responses in chronic persistent tuberculosis: possible role for limiting pathology. Infection Immunity 2001; 69: 1847-55.
23. SENALDI G, YIN S, SHAKLEE CL, PIGUET PF, MAK TW, ULICH TR: Corynebacterium parvum- and Mycobacterium bovis bacillus Calmette-Guerin-induced granuloma formation is inhibited in TNF receptor I (TNF-RI) knockout mice and by treatment with soluble TNF-RI. J Immunol 1996; 157: 5022-6.
24. National Cancer Institute: Surveillance, Epidemiology, and End Results (SEER) Database. Kosary 1995, SEER Stat for Windows 95/NT; 1997.
25. BAECKLUND E, EKBOM A, SPAREN P, FELTELIUS N, KLARESKOG L: Disease activity and risk of lymphoma in patients with rheumatoid arthritis: Nested case-control study. BMJ 1998; 317: 180-1.
26. GRIDLEY G, McLAUGHLIN JK, EKBOM A, et al.: Incidence of cancer among patients with rheumatoid arthritis. J Natl Cancer Inst 1993; 85: 307-11.
27. ASTEN P, BARRETT J, SYMMONS D: Risk of developing certain malignancies is related to duration of immunosuppressive drug exposure in patients with rheumatic diseases. J Rheumatol 1999; 26: 1705-14.